28 October 2025
Jean-Paul Borg discusses the advances made by teams in Marseille in the fields of molecular medicine, immunotherapy and targeted therapies.
24 September 2025
Nearly 45 participants from the OHIO department gathered for a morning of fun and conviviality.
24 September 2025
Anne-Sophie Chrétien, Frédéric Bard and Brice Chanez - all three recipients of specific "Pancreatic Cancer" funding from the ARC Foundation -.
20 February 2025
The team has just received pre-maturation funding from Cancéropôle PACA for its project to validate a biomarker predictive of the eligibility of patients with acute myeloid leukemia (AML) for treatment with menin inhibitors.
28 January 2025
Published in Cellular and Molecular Gastroenterology and Hepatology, the De Sepulveda team's study demonstrates that the MAN2A1-FER oncoprotein, present in several cancers, lacks kinase activity, calling into question the efficacy of tyrosine kinase inhibitors as a therapeutic strategy.
28 January 2025
The new ANR-funded project will explore the non-canonical roles of CDK6 and pave the way for innovative leukemia treatments using advanced models and drug repositioning strategies.
28 January 2025
Published in ACS Nano, the study deciphers the impact of biophysical parameters and individual immune response on the efficacy of immune cell engagers, paving the way for optimizing their design in immunotherapy.
28 January 2025
The ATI team celebrates a double victory with prestigious funding for its innovative immunotherapy projects.
14 January 2025
Published by Poplineau et al. in 2022, the article "Noncanonical EZH2 drives retinoic acid resistance in AML by repressing retinoic acid targets" made the cover of the issue.
26 November 2024
Over a hundred people have come to learn and develop the research carried out by the team.